Melanoma prognostics and personalized therapeutics at a crossroad

Journal of Investigative Dermatology

Volumn 133, Issue 2, 2013, Pages 292-295

  Lo, Roger S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; B RAF KINASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PEGINTERFERON; PROGRAMMED DEATH 1 RECEPTOR; TRASTUZUMAB;

CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CELL INTERACTION; DRUG MEGADOSE; GENE MUTATION; HUMAN; MELANOMA; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; UPREGULATION;

EID: 84872554465     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.386     Document Type: Note

References (13)

1. Brahmer JR, Tykodi SS, Chow LQ et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-65
2. Chapman PB, Hauschild A, Robert C et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-16
3. Long GV, Menzies AM, Nagrial AM et al. (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29:1239-46
4. Mann GJ, Pupo GM, Campain AE et al. (2012) BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invest Dermatol 133:509-17
5. Moreau S, Saiag P, Aegerter P et al. (2012) Prognostic value of BRAF (V600) mutations in melanoma patients after resection of meta-static lymph nodes. Ann Surg Oncol; e-pub ahead of print 7 July 2012
6. Nazarian R, Shi H, Wang Q et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-7
7. Poulikakos PI, Persaud Y, Janakiraman M et al. (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480:387-90
8. Shi H, Moriceau G, Kong X et al. (2012) Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 3:724
9. Sosman JA, Kim KB, Schuchter L et al. (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-14
10. Su F, Viros A, Milagre C et al. (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366:207-15
11. Topalian SL, Hodi FS, Brahmer JR et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-54
12. Villanueva J, Vultur A, Lee JT et al. (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18: 683-95
13. Wagle N, Emery C, Berger MF et al. (2011) Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29:3085-96